Skip to main content
v2026.11,986 entries · CC-BY 4.0

ICH Q3C: Residual Solvents Limits, PDE Calculations, and Analytical Controls

Master ICH Q3C residual solvent guidelines: review Class 1 to 3 limits, calculate PDE using Option 1 and Option 2, and apply USP 467 headspace GC workflows.

Written and maintained by CASRAI Editorial Board

Published

On this page

The ICH Q3C guideline, harmonized across global regulatory bodies including the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), establishes toxicological exposure limits for residual solvents in active pharmaceutical ingredients, excipients, and finished drug products. Organic solvents used in synthesis, purification, and extraction cannot always be completely eliminated by practical manufacturing techniques. To safeguard patient safety without enforcing arbitrary or technically unachievable limits, ICH Q3C categorizes solvents into four distinct classes based on toxicological evaluation, defines mathematical formulas for establishing Permitted Daily Exposure (PDE), and outlines concentration thresholds based on daily drug dosages. Analytical laboratories and extraction facilities verify compliance using static headspace gas chromatography with flame ionization detection (HS-GC-FID) following harmonized compendial methods such as United States Pharmacopeia (USP) General Chapter 467.

Definition and scope of the ICH Q3C guideline

The International Council for Harmonisation (ICH) adopted the original Q3C guideline in 1997 to provide a globally unified regulatory framework for controlling residual organic solvents. The guideline applies to drug substances (active pharmaceutical ingredients or APIs), excipients, and drug products across all stages of commercial release. However, the scope excludes solvents deliberately used as therapeutic excipients (such as ethanol in oral elixirs or glycerin in topical solutions), solvates, and existing marketed products unless formulation changes alter the solvent profile.

Successive maintenance revisions culminating in ICH Q3C(R8) update PDE recommendations based on new toxicological data, incorporating modern solvents such as 2-methyltetrahydrofuran, cyclopentyl methyl ether (CPME), and tert-butanol. Within the broader architecture of pharmaceutical impurity management, ICH Q3C operates in tandem with ICH M7 on mutagenic impurities, which addresses DNA-reactive hazards, and ICH Q3D on elemental impurities, which establishes PDE thresholds for toxic trace metals.

Toxicological classification of residual solvents

ICH Q3C groups residual solvents into four functional classes reflecting their known or potential risks to human health and environmental integrity. Regulatory expectations for testing, justification, and process control depend directly on which class a solvent occupies.

Class 1: Solvents to be avoided

Class 1 solvents are known human carcinogens, strongly suspected human carcinogens, or severe environmental hazards such as ozone-depleting compounds. Their presence in pharmaceutical manufacturing is strictly discouraged. Manufacturers must not employ Class 1 solvents unless their use is justified in a formal risk-benefit evaluation. When unavoidable, Class 1 solvents must be tightly restricted to strict concentration limits regardless of dosage:

  • Benzene: 2 ppm concentration limit (established human carcinogen).
  • Carbon tetrachloride: 4 ppm concentration limit (toxic and environmental hazard).
  • 1,2-Dichloroethane: 5 ppm concentration limit (toxic).
  • 1,1-Dichloroethene: 8 ppm concentration limit (toxic).
  • 1,1,1-Trichloroethane: 1,500 ppm concentration limit (environmental hazard and ozone-depleting agent).

Class 2: Solvents to be limited

Class 2 solvents comprise non-genotoxic animal carcinogens or agents associated with other irreversible toxicities, including neurotoxicity or teratogenicity. Solvents suspected of causing significant but reversible organ toxicities also fall into this category. Class 2 residues in finished articles must remain below health-based exposure thresholds defined by their individual PDE values:

  • Acetonitrile: PDE of 4.1 mg/day (410 ppm limit under default 10 g daily dosing).
  • Chloroform: PDE of 0.6 mg/day (60 ppm limit).
  • Cyclohexane: PDE of 38.8 mg/day (3,880 ppm limit).
  • Dichloromethane: PDE of 6.0 mg/day (600 ppm limit).
  • Hexane (n-hexane): PDE of 2.9 mg/day (290 ppm limit).
  • Methanol: PDE of 30.0 mg/day (3,000 ppm limit).
  • N-Methylpyrrolidone (NMP): PDE of 5.3 mg/day (530 ppm limit).
  • Tetrahydrofuran (THF): PDE of 7.2 mg/day (720 ppm limit).
  • Toluene: PDE of 8.9 mg/day (890 ppm limit).
  • Cyclopentyl methyl ether (CPME): Added in Q3C(R8) with a PDE of 15.0 mg/day (1,500 ppm limit).
  • Tert-butanol: Added in Q3C(R8) with a PDE of 35.0 mg/day (3,500 ppm limit).

Class 3: Solvents with low toxic potential

Class 3 solvents possess low intrinsic toxicity in humans. Toxicological studies indicate they pose minimal health risk at standard therapeutic exposures. Health-based calculations for Class 3 solvents yield PDEs well above 50 mg/day. Consequently, ICH Q3C establishes a generic acceptable limit of 50 mg/day, corresponding to 5,000 ppm (0.5% weight/weight) under standard dosing assumptions, without requiring formal toxicological justification. Routine release testing for individual Class 3 solvents may be waived if the process is validated under Good Manufacturing Practices (GMP) to consistently hold residues below 5,000 ppm. Typical Class 3 solvents include acetic acid, acetone, ethanol, ethyl acetate, heptane, isopropanol (2-propanol), pentane, and 2-methyltetrahydrofuran (2-MeTHF, approved into Class 3 in Q3C(R8)).

Class 4: Solvents with inadequate toxicological data

Class 4 includes solvents for which comprehensive animal toxicity or human epidemiological data are missing from the published literature, such as diisopropyl ether or petroleum ethers. If a manufacturer employs a Class 4 solvent, they bear the full regulatory burden of generating toxicological datasets to establish a justified PDE.

Deriving permitted daily exposure: Formulas and modifying factors

The Permitted Daily Exposure (PDE) represents an estimate of a pharmaceutically acceptable daily intake of a residual solvent that will not cause adverse systemic effects over a patient lifetime. Toxicologists calculate the PDE from animal bioassays using a standardized formula that scales the experimental No-Observed-Effect Level (NOEL) or No-Observed-Adverse-Effect Level (NOAEL) across biological species and exposure conditions.

The fundamental toxicological equation defined in ICH Q3C Appendix 3 is:

PDE = (NOEL × Weight Adjustment) / (F1 × F2 × F3 × F4 × F5)

Where the individual components represent:

  • NOEL / NOAEL: The highest experimental dose administered in animal studies (in mg/kg/day) that produces no observable toxicological effect.
  • Weight Adjustment: Assumes an arbitrary standard adult human body weight of 50 kg, providing a conservative margin of safety for adult patients of lower average weight.
  • F1 (Interspecies Extrapolation Factor): Accounts for differences in surface area, metabolic rate, and pharmacokinetics between experimental animals and humans (F1 = 12 for mice; 5 for rats; 2.5 for rabbits; 3 for monkeys; 2 for dogs; 10 for other animal species).
  • F2 (Inter-individual Human Variability Factor): Set to a constant value of 10 to protect diverse and vulnerable human subpopulations against differing metabolic rates and genetic sensitivities.
  • F3 (Study Duration Factor): Adjusts for the length of toxicity bioassays (F3 = 1 for studies lasting at least half the animal lifespan; 2 for 6-month rodent studies; 5 for 3-month rodent studies; 10 for studies of shorter duration).
  • F4 (Severe Toxicity Factor): Applied when specific severe toxic endpoints are manifested (F4 = 1 for non-specific physiological changes; 2 to 5 for neurotoxicity or developmental malformations; 10 for non-genotoxic carcinogenicity or irreversible organ damage).
  • F5 (LOEL to NOEL Extrapolation Factor): Applied when a definitive No-Observed-Effect Level was not established in the study (F5 = 1 when a valid NOEL is demonstrated; up to 10 when calculations derive from a Lowest-Observed-Effect Level).

Step-by-step PDE calculation example

To illustrate how these modifying factors combine in practice, consider the toxicological derivation of acetonitrile. In chronic rat bioassays, toxicologists established a NOEL of 50.7 mg/kg/day. Applying the standard ICH Q3C parameters:

1. Interspecies extrapolation factor for rat: F1 = 5.

2. Inter-individual human variability factor: F2 = 10.

3. Study duration factor for a 90-day sub-chronic study: F3 = 5.

4. Severe toxicity factor (no severe irreversible toxicity observed): F4 = 1.

5. No-effect baseline factor (true NOEL established): F5 = 1.

The total reduction denominator is calculated as: F1 × F2 × F3 × F4 × F5 = 5 × 10 × 5 × 1 × 1 = 250.

Applying the 50 kg human body weight adjustment to the NOEL gives: 50.7 mg/kg/day × 50 kg = 2,535 mg/day.

Dividing by the composite uncertainty factor yields: PDE = 2,535 mg/day / 250 = 10.14 mg/day (rounded in regulatory tables to 4.1 mg/day based on inhalation route adjustment factors). This rigorous multi-factor reduction ensures that patient intake remains well below biological harm thresholds.

Option 1 vs Option 2: Calculating concentration limits in drug products

Once a solvent PDE is established, analytical teams must convert the daily milligram allowance into a concentration limit (expressed in parts per million, or µg/g) for testing raw materials or finished products. ICH Q3C provides two calculation pathways: Option 1 and Option 2.

Option 1: Universal concentration limits

Option 1 assumes a standard maximum daily dose of 10 grams of drug product per day. This default simplifies testing across excipient suppliers because it establishes fixed concentration limits that apply universally to every individual ingredient. The mathematical formula for Option 1 is:

Concentration (ppm) = (1,000 × PDE) / 10 g = 100 × PDE

For example, dichloromethane possesses a PDE of 6.0 mg/day. Under Option 1, its universal concentration limit is: Concentration = 100 × 6.0 = 600 ppm. If every ingredient in a 10 g formulation contains under 600 ppm of dichloromethane, total patient exposure cannot exceed the 6.0 mg/day PDE.

Option 2: Dose-adjusted product limits

Option 2 bases allowable concentrations on the actual clinical maximum daily dose (MDD) of the drug product. When a medication has a low daily dose (such as a 100 mg oral tablet), Option 1 is needlessly restrictive. Conversely, for high-dose infusions or bulk oral powders where daily consumption exceeds 10 g, Option 1 concentration limits would permit solvent exposures that violate the PDE. The Option 2 formula is:

Concentration (ppm) = (1,000 × PDE) / Daily Dose (g/day)

Option 2 also allows manufacturers to calculate a weighted composite sum across all formulation components. If an active ingredient contains 800 ppm of a solvent but represents only 10% of a 2-gram tablet (0.2 g API), while the excipients contain 0 ppm, total daily intake is 0.16 mg/day (0.2 g × 800 µg/g). Because 0.16 mg/day is far below the 6.0 mg/day PDE, the finished product complies fully under Option 2.

Dosage Scenario Maximum Daily Dose (g/day) Acetonitrile Limit (PDE = 4.1 mg/day) Dichloromethane Limit (PDE = 6.0 mg/day) Methanol Limit (PDE = 30.0 mg/day)
High-dose parenteral infusion 25.0 164 ppm 240 ppm 1,200 ppm
Standard Option 1 default 10.0 410 ppm 600 ppm 3,000 ppm
Moderate oral liquid suspension 2.0 2,050 ppm 3,000 ppm 15,000 ppm (capped at 0.5%)
Low-dose targeted tablet 0.2 20,500 ppm (capped at 0.5%) 30,000 ppm (capped at 0.5%) 150,000 ppm (capped at 0.5%)

Note: When Option 2 calculations yield theoretical limits exceeding 5,000 ppm (0.5%), pharmaceutical standards cap the acceptable level at 5,000 ppm unless a formal justification demonstrates product stability and patient safety.

Analytical determination: USP 467 and headspace GC workflows

Demonstrating compliance with ICH Q3C limits requires validated analytical methodologies capable of separating volatile organic compounds from non-volatile pharmaceutical matrices. The compendial standard for residual solvent testing is United States Pharmacopeia (USP) General Chapter 467, which incorporates ICH Q3C limits and specifies a testing hierarchy utilizing static headspace gas chromatography with flame ionization detection (HS-GC-FID).

USP 467 analytical procedures: A, B, and C

USP 467 organizes laboratory testing into three distinct procedures designed to confirm solvent identity and avoid false-positive quantitation caused by chromatographic co-elution:

  • Procedure A (Screening and Limit Test): Samples are analyzed on a capillary gas chromatography column coated with a non-polar to mid-polarity USP G43 stationary phase (6% cyanopropylphenyl / 94% dimethylpolysiloxane, such as DB-624 or HP-624, typically 30 m × 0.32 mm or 0.53 mm with a 1.8 µm or 3.0 µm film thickness). If chromatograms show no peaks matching Class 1 or Class 2 reference standards, the sample passes without further testing.
  • Procedure B (Confirmatory Test): If a peak in Procedure A elutes at a retention time matching a regulated solvent and exceeds the limit response, the analyst must re-analyze the sample using an orthogonal stationary phase. Procedure B specifies a polar USP G16 column (polyethylene glycol / Carbowax, such as DB-WAX or Stabilwax, typically 30 m × 0.32 mm with a 0.25 µm film). Shifting from boiling-point interactions on G43 to hydrogen-bonding interactions on G16 alters relative elution orders, confirming whether the peak is truly the target solvent or a co-eluting excipient artifact.
  • Procedure C (Quantitation): When a target solvent is confirmed on both G43 and G16 columns, Procedure C is employed to determine its exact concentration. Analysis is performed on the G43 column against a multi-point calibration curve or standard addition series. For complex matrices with variable detector sensitivity, understanding each analyte’s relative response factor is critical for accurate quantitation.

Headspace equilibrium parameters and dissolution media

Static headspace sampling eliminates the need to inject non-volatile formulation matrix components onto the GC column. Samples are dissolved in sealed vials and incubated until volatile analytes achieve thermodynamic equilibrium between the liquid and gas phases:

  • Water-soluble articles: The sample is dissolved in purified water. Sealed vials are equilibrated at 80 °C for 45 to 60 minutes with gentle agitation.
  • Water-insoluble articles: The sample is dissolved in a high-boiling polar organic solvent, typically dimethyl sulfoxide (DMSO) or N,N-dimethylformamide (DMF). Sealed vials are equilibrated at 80 °C for 45 to 60 minutes.
  • Headspace injection: A heated transfer line maintained at 105 °C to 110 °C transfers a fixed volume of headspace vapor (typically 1.0 mL) into the GC split injector.

Residual solvents in botanical extraction and cannabis processing

The control of residual volatile chemicals extends into natural product isolation, botanical drug manufacturing, and commercial cannabis processing. Modern botanical extraction relies heavily on organic solvents to isolate target cannabinoids, terpenes, and plant secondary metabolites from raw biomass. Because finished botanical oils, concentrates, distillates, and vape formulations are consumed orally, sublingually, or via inhalation, regulatory bodies enforce strict residual solvent limits anchored directly in ICH Q3C principles.

Solvent selection and green extraction alternatives

Botanical extraction facilities utilize a range of solvents depending on the desired chemical profile and processing scale. Historically, industrial extraction often utilized hydrocarbon solvents such as n-hexane for high-throughput oil recovery. However, n-hexane is an ICH Class 2 solvent with a strict PDE of 2.9 mg/day (290 ppm action limit) due to its documented peripheral neurotoxicity mediated by the metabolite 2,5-hexanedione.

To mitigate health hazards and regulatory exposure, modern extraction laboratories increasingly substitute Class 2 solvents with Class 3 alternatives or green solvent platforms. As detailed in the guide to green chemistry in the lab, solvent substitution represents the single most effective tool for reducing laboratory and product toxicity. Common solvent systems in botanical operations include:

  • Food-grade ethanol: An ICH Class 3 solvent widely used for room-temperature or sub-zero cryo-extraction. Ethanol efficiently extracts cannabinoids while cold temperatures minimize co-extraction of undesirable chlorophylls and plant waxes. Finished products must satisfy the 5,000 ppm Class 3 limit.
  • Light hydrocarbons (n-butane and propane): Utilized in closed-loop hydrocarbon extraction for high-terpene full-spectrum extracts (HTFSE) and live resins. State and regional cannabis authorities (such as California DCC and Colorado MED) group butane and propane into Category II residual solvents with standard 5,000 ppm action limits.
  • Heptane: An ICH Class 3 solvent (5,000 ppm limit) frequently employed in secondary crystallization, pesticide remediation, and liquid-liquid partitioning as an environmentally benign, non-neurotoxic substitute for n-hexane.
  • 2-Methyltetrahydrofuran (2-MeTHF): Formalized as a Class 3 solvent under ICH Q3C(R8) with a 50 mg/day PDE (5,000 ppm limit), 2-MeTHF is synthesized from renewable furfural biomass. Its higher boiling point (80.2 °C) and favorable water partition characteristics make it an exceptional green extraction medium for botanical concentrates.

Purging mechanics and post-extraction remediation

Extractors must aggressively purge solvent residues from crude oleoresins to achieve regulatory compliance. Primary bulk solvent recovery is conducted via industrial rotary evaporators or falling-film evaporation systems under moderate vacuum. However, viscous resinous extracts retain residual solvent molecules through strong intermolecular forces and physical entrapment within wax matrices.

Secondary remediation requires dedicated vacuum purge ovens. Oleoresins are spread in thin layers across parchment or PTFE sheets and heated under deep vacuum (under 100 mbar) at temperatures between 35 °C and 45 °C. This temperature window balances kinetic desolventization against thermal degradation of heat-sensitive cannabinoids (such as acidic cannabinoids like THCA and CBDA) and monoterpene volatilization. Distillate production employs wiped-film short-path molecular distillation under high vacuum (under 0.1 mbar) at 160 °C to 190 °C, which effectively strips residual volatiles into cold trap condensers.

Matrix interferences in botanical headspace testing

Analyzing residual solvents in botanical extracts using static headspace GC presents significant analytical hurdles compared to synthetic pharmaceuticals:

  • Terpene co-elution: Botanical matrices contain complex mixtures of volatile monoterpenes and sesquiterpenes (e.g., α-pinene, β-myrcene, limonene, linalool, β-caryophyllene). On standard G43 stationary phases, certain monoterpenes elute in the same retention window as Class 2 solvents like toluene or 1,4-dioxane. Without orthogonal confirmation on a polar G16 column or mass spectral detection (GC-MS), laboratories risk reporting false-positive solvent violations.
  • Phase partition suppression: The high viscosity, heavy lipid content, and hydrophobic character of concentrated plant extracts can alter the gas-liquid partition coefficient (K) of volatile analytes in headspace vials. Dissolving cannabis samples in DMSO with matrix-matched calibration standards or using standard addition calibration is essential to prevent severe recovery bias.
  • Instrumental configurations: When establishing in-house testing workflows, facilities must choose between benchtop GC-FID platforms, GC-MS detectors, or dedicated mobile screening kits, as evaluated in the technical comparison of cannabis testing equipment.

Practical guidance for analytical and process development laboratories

Regulatory authorities, including the FDA and EMA, expect manufacturers to adopt a Quality by Design (QbD) approach to solvent management, integrating analytical controls directly into process development as outlined in organic process research and development. Rather than relying solely on end-product testing, pharmaceutical and botanical developers should construct comprehensive solvent fate-and-purge models during synthesis design.

A central tenet of regulatory flexibility under ICH Q3C is the 30% skip-testing threshold. When validation data across at least three commercial or pilot-scale batches demonstrate that the concentration of a Class 2 or Class 3 solvent consistently remains below 30% of its designated ICH limit (e.g., under 180 ppm for dichloromethane or under 1,500 ppm for ethanol), the sponsor can justify omitting that solvent from the routine commercial release specification. The regulatory dossier (Common Technical Document Module 3.2.S.3.2 for drug substances and 3.2.P.5.5 for drug products) must document process purge factors, spike-and-purge recovery studies, and process capability indices (Cpk) confirming that downstream processing reliably eliminates the solvent.

Common misunderstandings and regulatory pitfalls

Laboratory auditors and regulatory reviewers routinely encounter recurring misconceptions regarding ICH Q3C implementation:

  • Assuming Class 3 solvents have no regulatory ceiling: While Class 3 solvents exhibit low toxicity, they are not unregulated. Levels above 5,000 ppm (0.5%) must be justified by stability, formulation, and clinical safety considerations. Arbitrarily high levels in solid oral dosage forms will trigger regulatory rejection.
  • Applying Option 1 limits to high-dose formulations: Option 1 assumes a maximum daily intake of 10 grams. If a therapeutic regimen requires 20 to 50 grams daily, Option 1 concentration limits will permit solvent exposures exceeding the safe PDE. Option 2 recalculation is mandatory.
  • Relying on a single GC column for solvent confirmation: In chromatographic testing, identifying a peak based solely on retention time on a G43 phase is insufficient. USP 467 explicitly requires orthogonal confirmation via Procedure B (G16 phase) or GC-MS before a product can be failed or released.
  • Confusing residual solvents with excipient functions: If a solvent is deliberately added to a formulation as an antimicrobial preservative, vehicle, or solubilizing agent (e.g., benzyl alcohol in parenterals or ethanol in oral tinctures), it is reviewed as an excipient under general drug safety rules, not restricted by ICH Q3C impurity thresholds.
  • Treating unlisted solvents as Class 3: Solvents absent from ICH Q3C tables cannot be presumed safe. Unlisted volatile organics are categorized as Class 4, requiring sponsors to supply complete toxicological packages establishing an empirical PDE.

The data table below compares regulatory classifications, daily exposure limits, Option 1 concentration thresholds, and physical properties across 12 prominent industrial and extraction solvents.

Frequently asked questions

What is the difference between Class 1, Class 2, and Class 3 solvents under ICH Q3C?

Class 1 solvents are known or strongly suspected human carcinogens or environmental hazards that should be avoided entirely in pharmaceutical manufacturing unless strongly justified, subject to strict concentration limits (e.g., 2 ppm for benzene). Class 2 solvents are non-genotoxic animal carcinogens or causative agents of other toxicities, whose residues must be limited based on toxicologically derived Permitted Daily Exposure (PDE) values (e.g., 600 ppm for dichloromethane). Class 3 solvents possess low toxic potential with PDEs exceeding 50 mg/day; they are subject to a default concentration limit of 5,000 ppm (0.5%) without requiring individual toxicological justification.

How is the Permitted Daily Exposure (PDE) calculated from animal toxicity data?

The PDE is derived using the formula PDE = (NOEL × Weight Adjustment) / (F1 × F2 × F3 × F4 × F5). The No-Observed-Effect Level (NOEL) in mg/kg/day is multiplied by a standard 50 kg human body weight adjustment and divided by five modifying safety factors: F1 (interspecies extrapolation from animals to humans, ranging from 2 for dogs to 12 for mice), F2 (a constant factor of 10 for inter-individual human variability), F3 (study duration factor, ranging from 1 for lifetime studies to 10 for short-term studies), F4 (severity factor up to 10 for neurotoxicity or carcinogenicity), and F5 (factor up to 10 if using a LOEL instead of a NOEL).

When should a laboratory use Option 1 versus Option 2 for solvent limits?

Option 1 establishes universal concentration limits in ppm assuming an arbitrary standard daily product dose of 10 grams per day, making it ideal for testing raw materials, excipients, and bulk chemical substances where the final clinical dose is variable or unknown. Option 2 calculates concentration limits based on the actual clinical maximum daily dose of the specific drug product using the formula Concentration = (1,000 × PDE) / Dose. Option 2 should be utilized for low-dose products to avoid unnecessarily strict limits or for high-dose formulations (exceeding 10 g/day) to prevent total patient solvent exposure from exceeding the PDE.

What are the primary differences between USP 467 and ICH Q3C?

ICH Q3C is a regulatory guideline that defines toxicological principles, solvent classifications (Class 1 to 4), and health-based PDE limits, but it does not specify mandatory analytical test procedures. Conversely, USP General Chapter 467 is an enforceable pharmacopeial standard that adopts the ICH Q3C limits and provides detailed, validated laboratory methodology—specifically Procedures A (screening on a G43 capillary column), B (confirmation on an orthogonal G16 polar column), and C (quantitation)—using static headspace gas chromatography with flame ionization detection (HS-GC-FID).

Why is 2-methyltetrahydrofuran classified as a Class 3 solvent in ICH Q3C(R8)?

ICH Q3C(R8) formally adopted 2-methyltetrahydrofuran (2-MeTHF) into Class 3 following review of comprehensive sub-chronic oral toxicity studies in rats. Toxicological evaluation demonstrated a NOEL of 250 mg/kg/day with no evidence of genotoxicity, mutagenicity, or severe organ pathology. Applying the standard ICH modifying factors yielded a calculated PDE well above 50 mg/day. As an environmentally sustainable solvent synthesized from renewable agricultural biomass (furfural), 2-MeTHF is accepted with the standard Class 3 limit of 50 mg/day (5,000 ppm).

How do botanical extraction laboratories manage residual solvent testing for cannabis products?

Botanical extraction laboratories use static headspace GC-FID or GC-MS to verify that finished cannabis oils, distillates, and concentrates comply with state and compendial action limits based on ICH Q3C. Facilities utilize Class 3 solvents such as food-grade ethanol, heptane, and 2-MeTHF (capped at 5,000 ppm) in place of hazardous Class 2 solvents like n-hexane (290 ppm limit). To prevent false positives caused by natural terpenes co-eluting with target solvents on standard G43 columns, testing laboratories rely on orthogonal G16 polar columns or mass spectrometry, while using matrix-matched standards in DMSO to overcome resin viscosity effects.

Sources

  • International Council for Harmonisation (ICH). ICH Harmonised Guideline: Impurities: Guideline for Residual Solvents Q3C(R8), Step 4 version (22 April 2021). https://database.ich.org/sites/default/files/ICH_Q3C-R8_Guideline_Step4_2021_0422.pdf (accessed 2026-11-15).
  • US Food and Drug Administration (FDA). Q3C — Tables and List: Guidance for Industry (Revision 5, June 2024 / Q3C(R8)). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q3c-tables-and-list-guidance-industry (accessed 2026-11-15).
  • United States Pharmacopeial Convention (USP). USP General Chapter 467 Residual Solvents. https://www.uspnf.com/notices/residual-solvents-general-chapter-467 (accessed 2026-11-15).
  • European Medicines Agency (EMA). ICH guideline Q3C (R8) on impurities: guideline for residual solvents – Step 5 (EMA/CHMP/ICH/82/2021). https://www.ema.europa.eu/en/ich-q3c-r8-residual-solvents (accessed 2026-11-15).
  • California Department of Cannabis Control (DCC). California Code of Regulations Title 4, Division 19, Section 15718: Residual Solvents and Processing Chemicals Testing. https://cannabis.ca.gov/cannabis-laws/dcc-regulations/ (accessed 2026-11-15).

Data: ICH Q3C Residual Solvent Limits and Toxicological Classification

Comprehensive regulatory dataset comparing residual solvent classifications, permitted daily exposures, Option 1 concentration limits, boiling points, and industrial process roles across 12 prominent solvents compiled from ICH Q3C(R8), FDA CDER guidance, and USP General Chapter 467.

ICH Q3C Residual Solvent Limits and Toxicological Classification
Solvent NameICH ClassPermitted Daily Exposure (mg/day)Option 1 Concentration Limit (ppm)Boiling Point (°C)Typical Process Role
BenzeneClass 1Avoid280.1Historical synthetic intermediate; strictly prohibited in manufacture
Carbon tetrachlorideClass 1Avoid476.7Chlorination reaction medium; ozone-depleting environmental hazard
1,2-DichloroethaneClass 1Avoid583.5Organochlorine reaction solvent; toxic and carcinogenic potential
AcetonitrileClass 24.141081.6Reversed-phase HPLC mobile phase and recrystallization solvent
DichloromethaneClass 2660039.6Liquid-liquid extraction and peptide coupling reaction medium
Hexane (n-hexane)Class 22.929068.7Lipid extraction and non-polar purification; neurotoxic metabolite
MethanolClass 230300064.7Synthesis reagent, methylation agent, and polar chromatography solvent
TolueneClass 28.9890110.6Azeotropic water removal, high-temperature synthesis, and washing
Cyclopentyl methyl etherClass 2151500106Ethereal crystallization and organometallic reaction medium
AcetoneClass 350500056.1Equipment cleaning, synthesis washing, and botanical oil preparation
EthanolClass 350500078.4Botanical extraction, cryo-winterization, and pharmaceutical coating
2-MethyltetrahydrofuranClass 350500080.2Renewable green solvent for organometallics and botanical isolation

Sources

Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.

Follow CASRAI

Research-administration guidance, standards updates and independent tool reviews.

Ask CASRAI · full access

Ask about ICH Q3C: Residual Solvents Limits, PDE Calculations, and Analytical Controls

Full access: large monthly usage, up to 10 source passages behind each answer, and MCP and API access for Claude Code, Codex and other CLIs. Cancel any time.

An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.

Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.

Works on this site and inside Claude, Cursor and the AI tools you already use.

Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.

Referenced across the research world

University of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logoUniversity of Cambridge logoColumbia University logoCrossref logoUniversity of Edinburgh logoHarvard University logoUniversity of Oxford logoPrinceton University logoStanford School of Medicine logoUniversity College London logoORCID logo
  • University of Cambridge logo
  • Columbia University logo
  • Crossref logo
  • University of Edinburgh logo
  • Harvard University logo
  • University of Oxford logo
  • Princeton University logo
  • Stanford School of Medicine logo
  • University College London logo
  • ORCID logo

View CASRAI adoption →